Articles From: Intercontinental Exchange Reports ICE and NYSE Volume for December and Full Year 2014; 18th Consecutive Annual Brent ADV Record to Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit


Intercontinental Exchange (NYSE: ICE), the leading global network of exchanges and clearing houses, today reported December 2014, fourth quarter 2014 and full year 2014 exchange traded volume.
Sign-up for Intercontinental Exchange Reports ICE and NYSE Volume for December and Full Year 2014; 18th Consecutive Annual Brent ADV Record investment picks
Intercontinental Exchange (NYSE: ICE), the leading global network of exchanges and clearing houses, today reported monthly exchange traded volumes.
Sign-up for Intercontinental Exchange Reports ICE and NYSE Volume for November 2014; Natural Gas ADV up 19% year on year investment picks
Intercontinental Exchange, Inc. (NYSE: ICE), the leading global network of exchanges and clearing houses, today reported monthly exchange traded volumes.
Sign-up for Intercontinental Exchange Reports ICE and NYSE Volume for October 2014; Cash Equities ADV up 32% year on year investment picks
Intercontinental Exchange (NYSE: ICE), the leading global network of exchanges and clearing houses, today reported financial results for the third quarter of 2014.
Sign-up for Intercontinental Exchange Reports Third Quarter 2014 Results investment picks
Intercontinental Exchange (NYSE: ICE), the leading global network of exchanges and clearing houses, will announce fourth quarter 2014 financial results on Thursday, February 5, 2015.
Sign-up for Intercontinental Exchange Sets February 5 for Fourth Quarter 2014 Earnings Announcement investment picks
Intercontinental Exchange (NYSE: ICE), the leading global network of exchanges and clearing houses, announced today its intention to sell approximately 4.2 million shares in Euronext N.V., representing approximately 6% of Euronext’s share capital, by way of an accelerated book-building to institutional investors.
Sign-up for Intercontinental Exchange to Sell Remaining Shares in Euronext investment picks
2014/12/1
http://media.marketwire.com/attachments/201412/294073_icor_03.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1162347&ProfileId=051205&sourceType=1 DELRAY BEACH, FL --
Sign-up for InterCore's Driver Alertness Detection System(TM) Now Available investment picks
2014/12/1
InterCore, Inc. (OTC Pink:ICOR) ("InterCore") announces that DADS TM —the network-based D river A lertness D etection S ystem TM —is now available for purchase at DADS.SRGINT.com .
Sign-up for InterCore’s Driver Alertness Detection System™ Now Available investment picks
WILMINGTON, Del., Nov.
Sign-up for InterDigital Adds Former Nokia Executive Kai Oistamo to Board of Directors investment picks
WILMINGTON, Del., Oct.
Sign-up for InterDigital Announces Date for Third Quarter 2014 Financial Results investment picks
WILMINGTON, Del., Dec.
Sign-up for InterDigital Demonstrates M2M Standards Research at oneM2M Showcase Event investment picks
WILMINGTON, Del., Nov.
Sign-up for InterDigital Issues Revenue Guidance for Fourth Quarter 2014 investment picks
WILMINGTON, Del., Oct.
Sign-up for InterDigital Prevails Over ZTE in Delaware District Court investment picks
WILMINGTON, Del., Dec.
Sign-up for InterDigital Principal Engineer Named IEEE Fellow investment picks
WILMINGTON, Del., Oct.
Sign-up for InterDigital Third Quarter 2014 Financial Results Driven by 57% Increase in Recurring Revenue investment picks
WILMINGTON, Del., Nov.
Sign-up for InterDigital to Present at Barclays & NASDAQ OMX Conferences investment picks
WILMINGTON, Del., Jan.
Sign-up for InterDigital to Present at Needham Growth Conference investment picks
WILMINGTON, Del., Dec.
Sign-up for InterDigital's Board of Directors Declares Regular Quarterly Cash Dividend investment picks
WILMINGTON, Del., Dec.
Sign-up for InterDigital's Innovation Partners Enters Into Research Agreement With Germany's IfU investment picks
WILMINGTON, Del., Nov.
Sign-up for InterDigital's Innovation Partners Expands Its Relationship With McGill University in Canada investment picks
ATLANTA , Jan.
Sign-up for Interface Names Jay D. Gould Chief Operating Officer investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0984622001&sourceType=1 http://media3.marketwire.com/logos/20131106-200if.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Interfor Completes Debt Financing with Prudential Capital Group investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0984850001&sourceType=1 http://media3.marketwire.com/logos/20131106-200if.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Interfor Continues to Grow in the US investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0977599001&sourceType=1 http://media3.marketwire.com/logos/20131106-200if.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Interfor Reports Strong Results in Q3'14 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0987419001&sourceType=1 http://media3.marketwire.com/logos/20131106-200if.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Interfor to Announce Fourth Quarter and Fiscal 2014 Results on February 12, 2015 investment picks
93% (13/14) of evaluable CLL patients treated at dose levels ≥ 800mg of original formulation or any dose of the micronized formulation achieved a > 50% reduction in nodal size (a nodal PR) and 50% (7/14) achieved a partial response per iwCLL (Hallek 2008) criteria 100% (6/6) of CLL and iNHL patients achieving TGR-1202 drug concentrations above 4,000ng/ml responded at the first or second efficacy assessment with at least a nodal PR for CLL or PR for iNHL; Expansion cohorts now open at 800mg QD for CLL and 1200mg QD for iNHL, the dose level that appears to provide patients (3/3) with drug concentrations > 4,000ng/ml No drug related hepatic toxicity or colitis observed with 55 patients treated to date and median time on study of approximately 6 months and some patients on study for over 1.5 years TGR-1202 has been well-tolerated with no dose-related trends in adverse events observed and no MTD reached to date, dose escalation continues now at 1800mg QD SAN
Sign-up for Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
Sign-up for Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting® investment picks
Clovis Oncology (NASDAQ:CLVS) announced today updated findings from its ongoing Phase 2 clinical study of rociletinib (CO-1686), the Company’s novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of NSCLC in patients with initial activating EGFR mutations as well as the primary resistance mutation T790M.
Sign-up for Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) investment picks
-Benefit observed across multiple endpoints in bevacizumab-naïve patients- HAMPTON, N.J., Nov.
Sign-up for Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Intercontinental Exchange Reports ICE and NYSE Volume for December and Full Year 2014; 18th Consecutive Annual Brent ADV Record to Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent